March 2, 2019 | Jeju Island, South Korea

Viewpoint Co-Founder and Chief Science Officer Michael Schultz, PhD delivered an invited presentation at the 2019 Theranostics World Congress in Jeju, South Korea. This was the fifth occasion of the Theranostics World Congress, an event in attendance of leading experts with the point of discussing future prospects of expanding the use of theranostics in the health care system to new cancer types. Dr. Schultz presented “203Pb/212Pb Peptide Receptor Targeted Theranostics for Cancer” during the Next Generation Theranostics (from Chemists’ Point of View) – Alpha Emitters conference session.